BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2971 related articles for article (PubMed ID: 16911497)

  • 1. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin-inhibitor-sparing immunosuppressive protocols.
    Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
    Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
    Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitor-free protocols: risks and benefits.
    Barbari AG; Stephan AG; Masri MA
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin inhibitor sparing in renal transplantation.
    Ekberg H
    Transplantation; 2008 Sep; 86(6):761-7. PubMed ID: 18813097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
    Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
    Tredger JM; Brown NW; Dhawan A
    Drugs; 2008; 68(10):1385-414. PubMed ID: 18578558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor minimization protocols in liver transplantation.
    Farkas SA; Schnitzbauer AA; Kirchner G; Obed A; Banas B; Schlitt HJ
    Transpl Int; 2009 Jan; 22(1):49-60. PubMed ID: 19121146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing calcineurin inhibitor drugs in renal transplantation.
    Flechner SM
    Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we eliminate both calcineurin inhibitors and steroids?
    Lebranchu Y
    Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients.
    Mourer JS; de Koning EJ; van Zwet EW; Mallat MJ; Rabelink TJ; de Fijter JW
    Transplantation; 2013 Jul; 96(1):49-57. PubMed ID: 23715049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 149.